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Nanomechanical heterogeneity is expected to have an effect on elasticity, injury and bone remo-
delling. In normal bone, we have two types of cells (osteoclasts and osteoblasts) working together 
to maintain existing bone. Bone cancers can produce factors that make the osteoclasts work hard-
er. This means that more bone is destroyed than rebuilt, and leads to weakening of the affected bone. 
We report here the first demonstration of the nanoscale stiffness distribution in bone metastases 
before and after treatment of animals with the bisphosphonate Risedronate, a drug which is cur-
rently used for the treatment of bone metastases in patients with advanced cancers. The strategy 
used here is applicable to a wide class of biological tissues and may serve as a new reflection for 
biologically inspired scaffolds technologies. 
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As cancer becomes more advanced, it tends to spread throughout the body, with the bones being a common site 
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of spread for many cancers [1]. Spread of cancer to the bone from its original site is referred to as bone metas-
tases. Treatment may consist of radiation therapy, bisphosphonates, hormone therapy and/or chemotherapy, de-
pending upon the type of cancer from which the metastasis originated [2] [3]. 
Researchers are evaluating ways to avoid or decrease the ache or break caused by bone metastasis, not just 
provide treatment once they occur. Myeloma and some secondary bone cancers can produce factors that make 
the osteoclasts work harder [1]-[4]. This means that more bone is destroyed than rebuilt, and leads to weakening 
of the affected bone. This can cause pain and means that the bone can fracture or break more easily; in this case, 
ablation of metastasis bone and implantation of biomaterials are needed. 
As many natural materials, bone is heterogeneous. Mechanical heterogeneity is expected to exist at different 
length scales. It has become evident that the nanoscale properties of bone participate in its macroscopic biome- 
chanical funcion [4]-[7]. At the macroscopic level, considerable variations in mechanical properties have been 
detected for different tissues locations [8], as well as for regions within a specific location [9]. Microscopically, 
indentation has further identified differences in modulus and hardness for specific features such as lamellae (thin 
and thick) in osteons of bone which have been recognized as collagen fibril orientation, as well as variations in 
mineral composition [10] [11]. The cellular remodelling process resulting in a combination of new and old bone 
is a result of this heterogeneity at this length scale [12]. Atomic force microscopy (AFM)-based nanoindentation 
has been used to distinguish mechanically heterogeneous microscale regions in bone tissue from genetically 
modified mice [13]-[16]. These studies also raise important issues as to whether heterogeneity is advantageous 
or disadvantageous to the mechanical function of bone [17]. Recently, the detailed study of the consequences of 
heterogeneity, in particular at the nanoscale, was reported [18]. 
An inherent feature of bones is their heterogeneity in the collagen fibril orientation and the mineral content. 
This particular spatial structure has a direct incidence on their elasticity even on the nanometer scale [18]. The 
elasticity, or equivalently the stiffness, of a material can be quantified using nano-indentation. It consists in fix-
ing a probe (most often a sphere, a cone or a pyramid) at the end of the cantilever of an atomic force micro- 
scope (AFM) and to measure the deflection of the cantilever when the material to be characterized is pushed into 
contact with the probe. The applied force is derived from the deflection, and the indentation is derived from the 
deflection and the material displacement. In this way, we obtain a so-called force curve. If the material behaves 
as an elastic solid, a force curve can be interpreted using Hertzian mechanics [19]. This characterization method 
was used to compare healthy bone, bone with metastases, and bone after treatment with bisphosphonates. 
Bisphosphonates drugs are used for the treatment of cancer-related hypercalcemia and treatment of bone me-
tastases in patients with advanced cancers [2]. Bisphosphonates decrease the rate of bone destruction in patients 
with bone metastases and clinical studies have demonstrated that bisphosphonates can significantly decrease the 
pain and number of fractures induced by bone metastases. 
Bisphosphonates are established in the treatment of skeletal metastases [12]. They have a common P-C-P 
structural feature consisting in a central carbon atom correlated to two phosphonate moieties, and two substitu- 
ents (R1, R2) (Figure 1). Phosphonate and R1 (preferably hydroxyl) groups allow bisphosphonates to bind  
 
       
(a)                                     (b) 
Figure 1. (a) Chemical structure of bisphosphonate drugs. P-C-P common structural feature of bisphosphonates and location of 
the specific R1 and R2; (b) Chemical structure of the Risedronate (RIS) antitumor drug (2-(3-pyridinyl)-1-hydroxyethylidene- 
bisphosphonic acid).                                                                                         
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avidly to bone hydroxyapatite, while R2 determines their effectiveness to inhibit osteoclast-mediated bone re-
sorption [3]. Clinically, bisphosphonates significantly diminish bone destruction rate, pain and fractures asso-
ciated with bone metastases [2]. Moreover, there is extensive in vivo preclinical evidence that bisphosphonates 
reduce skeletal tumor burden and inhibit bone metastasis formation in animals [12]. Among proposed mechan-
isms of actions, bisphosphonates may render bone a less favorable microenvironment for metastasis develop-
ment by reducing osteoclast-mediated bone resorption, which, in turn, deprives tumor cells of bone-derived 
growth factors required for their proliferation. Additionally, bisphosphonates were shown to exert direct antitu-
mor action, as they inhibited tumor cell adhesion, invasion, and proliferation, and induced apoptosis of various 
human tumor cell lines in vitro [3]. However, to date this clear direct antitumor potential was not verified in vivo 
[10], due to the high affinity of bisphosphonates for bone mineral which must obstruct their availability for tu-
mor cells. We undeniably observed a significantly higher potency of soluble compared to mineral-bound bis-
phosphonates at inhibiting tumor cell adhesion to bone in vitro [1]. Therefore strategies are needed to optimize 
bisphosphonates bioavailability and direct antitumor activity in vivo. 
As well, cells are constantly changing their mechanical environment [20] and nanomechanical heterogeneity 
detection could facilitate damage detection in the extracellular matrix and improved remodelling responses. The 
heterogeneous nanomechanical prototypes measured experimentally could in turn induce local heterogeneous 
strains when loaded macroscopically. Such strains are expected to be increased by the softer surrounding cellu-
lar matrix of osteocytes [21] and also expected to influence interstitial fluid flow. 
The objective of this work was to analyze the nanomechanical distribution of breast cancer bone metastasis 
before and after treatment of metastatic animals with Risedronate, the usually administrated drug in clinic. In 
this study, we have first analyzed by radiography, histology and histomorphometry the legs from metastatic 
mice and compared them with those from animals that had not been injected with breast cancer cells (naive 
mice). 
By radiography, we have analyzed and compared the healthy bone without metastasis (Figure 2(a)), bone 
with metastasis induced after inoculation (Figure 2(b)) and the treated bone after treatment by Risedronate 
(Figure 2(c)). 
After radiography on day 32 after tumor cell injection, we have shown that metastatic animals had large osteolytic 
lesions in hind limbs when compared to the bones of naive mice (Figure 2, panels b vs a). Metastatic animals 
were then treated either with the bisphosphonate Risedronate (administered by subcutaneous injection in 
 
 
(a)                                  (b)                                       (c) 
Figure 2. Identification of bone metastasis on radiographs of hind limbs from mice not injected with tumor cells with healthy 
bone, Naïve (a); b and c radiographs were obtained from different mice at day 32 after CHO-β3 tumor cells inoculation. PBS 
was used as vehicle and corresponds to bone with metastasis (b); Risedronate was used to treat mice and the radiographs 
represent the treated bone (c). The radiographs displayed are examples that best illustrate the effects of treatments. Arrows 
indicate osteolytic lesions.                                                                                 
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PBS, used here as the vehicle) or the vehicle only. 
After radiographic analysis, we examined the effect of Risedronate on the extent of bone destruction and de-
termined the size of bone metastasis (Table 1). 
Our results indicate clearly the antitumor efficacy of the treatment by Risedronate (0.6 mm2 for treated bone, 
compared to 5 mm2 for bone without treatment). We also performed histology and compared tumor burden and 
soft tissue volume ratio before and after treatment by Risedronate (Figure 3 and Table 2). 
The images shown in Figure 3 are examples that best illustrate the effects of the treatments with Risedronate 
(Figure 3(c)) compared to no treated bone with tumor cells (asterisk in Figure 3(b)). To get more information 
 
 
Figure 3. Optical microscopy visualization after semi-thin section (7 µm) Histologic analysis of hind limbs from mice naïve 
with healthy bone (a); b and c were obtained from different mice at day 32 after CHO-β3 tumor cells inoculation. PBS was 
used as vehicle and corresponds to bone with metastasis (b); Risedronate was used to treat mice and represent the treated 
bone (c). After toluidine blue stain, bone is stained blue and tumor cells zone were represented by asterisk. The arrows 
indicate the bone marrow.                                                                                 
 
Table 1. Tumor size determination after radiography.                                                             
Treatment* Radiography (Tumor size (mm2/mouse) 
Naive “healthy bone” 0 
Vehicle “bone metastasis” 5 ± 0.6 
Risedronate “treated bone” 0.6 ± 0.08§ 
*Drug administration was initiated from the time of tumor cell inoculation (day 0) to the end of the protocol (day 32). All measurements were made 
32 days after tumor cell injection. Naive animals had not been injected with tumor cells and correspond to the healthy bone. PBS was used as vehicle 
for animals injected with tumor cells and correspond to bone metastasis. Risedronate animals treated by daily dose of 150 µg/kg, s.c. (clinical dose for 
patient with bone metastasis). Results are expressed as the mean ± SD (2 Naive mice, 3 Vehicle mice and 3 Risedronate mice). §P < 0.01, compared to 
the vehicle-treated group. Statistical pairwise comparisons were made using Mann-Whitney U test. 
 
Table 2. Histomorphometry from histology analysis.                                                             
Treatment* 
Histomorphometryخ 
BV/TV (%) TB/STV (%) 
Naive “healthy bone” 22.7 ± 1.8§ 0 
Vehicle “bone metastasis” 9.5 ± 2.6 42.4 ± 3.6 
Risedronate “treated bone” 33.2 ± 2.4§ 6.4 ± 3.4§ 
Naive animals are mice that had not been injected with tumor cells. Risedronate (150 µg/kg, daily) was administered to metastatic animals by subcu-
taneous injection in 0.1 mL PBS (vehicle). Control mice bearing metastatic lesions received a daily treatment with the vehicle only. *Drug administra-
tion was initiated from the time of tumor cell inoculation (day 0) to the end of the protocol (day 32). خHistomorphometry was performed on legs from 
naïve and metastatic animals. BV/TV: bone volume/tissue volume ratio (a measurement of the bone volume). TB/STV: tumor burden/soft tissue vo-
lume ratio (a measurement of the tumor volume). Results are expressed as the mean ± SD (2 Naive mice, 3 Vehicle mice and 3 Risedronate mice). §P 
< 0.01, compared to the vehicle-treated group. Statistical pairwise comparisons were made using Mann-Whitney U test. 
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concerning the quantification of bone, we analyzed finely by histomorphometry the histologic data and deter-
mined the ratio bone volume/tissue volume and tumor burden/soft tissues volume (Table 2). 
The beneficial effect of the treatment is demonstrated by the increase of the ratio BV/TV from 9.5% for bone 
without treatment to 33.2% for the treated bone. We have also shown that after treatment the ratio TB/STV was 
6.4% in comparison to 42.4% without treatment. 
Metastatic animals treated with Risedronate had osteolytic lesions that were 95% smaller than those of tu-
mor-bearing animals treated with the vehicle only (Table 1 and Figure 2(c)). Histologic analysis of hind limbs 
with metastases from vehicle-treated mice showed that tumor cells completely filled the bone marrow cavity and 
bone trabeculae were almost completely destroyed when compared to the bone histology of legs from naive 
mice (Figure 2, panels b vs a). By contrast, the extent of bone trabeculae in legs from Risedronate-treated mice 
was markedly increased, indicating a complete prevention of bone loss by the bisphosphonate (Figure 2(c)). In 
this respect, histomorphometric analysis of metastatic hind limbs from mice treated with Risedronate showed 
that the bone volume (BV) to tissue volume (TV) ratio was statistically significantly higher than that corres-
ponding to vehicle-treated animals and naive mice (Table 2 and Figure 2). Risedronate also decreased the tu-
mor burden (TB) to soft tissue volume (STV) ratio by 85% compared with vehicle (Table 2 and Figure 2). 
In order to get more information about the structure of bone after Risedronate treatment, we analyzed and 
compared by electron microscopy the bones from naive animals with those obtained from metastatic animals 
treated with the bisphosphonate. By optical microscopy, we visualized different cells (Figure 3) after semi-thin 
sections (7 µm) of the different bone and toluidine blue stain. Figure 3(b) shows the invasion of bone by tumor 
cells working harder to destroy bone. In Figure 3(a) and Figure 3(c), we have a normal bone with bone mar-
row section and mineralized bone with osteoblasts and osteoclasts. In Figure 3(c), we can also see more mine-
ralization than in Figure 3(a). This result could be explained by the capacity of Risedronate to induce minera-
lization. 
Bones from naive animals and metastatic animals treated or not with Risedronate were next analyzed by 
Atomic Force Microscopy (AFM) in order to examine the ultrastructure and nanomechanical spatial hetero- 
geneity of the bone tissue (Figure 4). 
The raw indentation curves were obtained by atomic force microscopy with diamond-like tip (Figure 4(a)). 
We report here the first demonstration of the ultrastructure and nanomechanical spatial heterogeneity of bone 
 
 
(a)                                                        (b) 
Figure 4. Representative raw indentation curves (a) and comparison of bone stiffness distribution (b). (a) Raw indentation 
curves obtained by atomic force microscopy with diamond like tip (100 nm of radius) for naïve healthy bone (black bar), 
vehicle bone with metastasis (red bar) and Risedronate treated bone (green bar) selected in the highest value of distribution. 
(b) Bone stiffness distributions for naive healthy bone (black bars) with a median of 8.14 GPa (first quartile = 6.39 GPa, 
third quartile = 10.33 GPa), for bone with metastasis and Risedronate treated bone (green bars) with a median of 5.45 GPa 
(first quartile = 3.49 GPa, third quartile = 8.08 GPa), and vehicle bone with metastasis (red bars) with a median of 2.38 GPa 
(first quartile = 1.60 GPa, third quartile = 3.39 GPa), obtained after computation of the elastic modulus from nanoindentation 
data.                                                                                                     
L. Richert et al. 
 
 224 
stiffness with metastasis and the effect of the treatment on this nanomechanical distribution. The distribution of 
elastic modulus highlights the major decrease of elastic modulus in bone with metastasis (see histograms above). 
The median value is divided by a factor larger than 3 (8.14 GPa for healthy bone, 2.38 GPa for bone with me-
tastasis). The Risedronate treatment reduces this decrease with an intermediate median value of 5.45 GPa. The 
differences in median and quartile interval underscore in particular the strong softening of malignant bone with 
respect to the healthy bone. Furthermore, it should be emphasized that the Risedronate treatment leads to a sig-
nificant recovering of the nanomechanical stiffness. To observe more finely these differences, spatial distribu-
tion of elastic modulus has been recorded (Figure 5). 
In Figure 5, for each nanoindentation data spaced of 300 nm, the elastic modulus is represented by a colour 
value. The three types of bone present heterogeneity in the spatial elastic modulus repartition (Figure 5(b), 
 
 
Figure 5. Ultrastructure and nanomechanical spatial heterogeneity of bone stiffness. (a) An a.c. intermittent contact-mode 
AFM height image (10 × 10 µm2) viewed perpendicular to the naive healthy bone axis with a RMS of 21.0 nm; (b) 2D 
contour map (10 × 10 µm2) of elastic modulus calculated from nanoindentation data (c) An a.c. intermittent contact-mode 
AFM height image (10 × 10 µm2) viewed perpendicular to the vehicle bone with metastasis axis with a RMS of 55.3 nm. (d) 
2D contour map (10 × 10 µm2) of elastic modulus calculated from nanoindentation data; (e) An a.c. intermittent 
contact-mode AFM height image (10 × 10 µm2) viewed perpendicular to the Risedronate treated bone axis with a RMS of 
50.1 nm; (f) 2D contour map (10 × 10 µm2) of elastic modulus calculated from nanoindentation data.                                    
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Figure 5(d), Figure 5(f)), but the bone with metastasis and Risedronate treatment is particular heterogeneous as 
revealed by the wide range of values of E present in the 10 × 10 µm2 sample (Figure 5(f)). 
In summary, bone is constantly being broken down and renewed. It is living tissue that needs exercise to gain 
strength. Bone metastasis occurs when cancer cells from the primary tumor relocate to the bone. Metastatic bone 
disease develops as a result of the many interactions between tumor cells and bone cells. This leads to distur-
bance of normal bone metabolism, with the increased osteoclast activity seen in most, if not all, tumor types 
providing a rational target for treatment. 
Like many natural materials, bone is mechanically heterogeneous with spatial distributions in the shape, size 
and composition of its constituent. It is expected that nanomechanical heterogeneity influence elasticity, damage, 
fracture and remodelling of bone. We report here the first demonstration of the nanoscale stiffness distribution in 
bone metastasis before and after treatment of animals with Risedronate, a drug which is currently used for the 
treatment of bone metastases in patients with advanced cancers. This concept is generally applicable to a broad 
class of natural materials because nanomechanical heterogeneity expected to be ubiquitously presented. 
2. Methods 
2.1. Specific Drug for Treatment 
Bisphosphonate Risedronate [2-(3-pyridinyl)1-hydroxyethylidene-bisphosphonic acid] was obtained from Proc-
ter and Gamble Pharmaceuticals (Mason, OH, USA). The drug was dissolved in water and stored at 4˚C. 
2.2. Mouse Model of Breast Cancer Bone Metastasis 
All procedures involving mice including their housing and care, the method by which they were killed, and all 
experimental protocols were conducted in accordance with a code of practice established by the ethical commit- 
tee in Lyon (France). This study was monitored on a routine basis by the attending veterinarian according to en-
sure continued compliance with the proposed protocols. Four-week-old female Balb/c athymic (nu/nu) mice 
were purchased from Charles River (St. Germain sur l’Arbresle, France). The bone metastasis experiments in 
mice were conducted as previously described, using B02 cells, a subpopulation of the human MDA-MB-231 
breast cancer cell line that was selected for the high efficiency with which it metastasizes to bone after intrave-
nous inoculation [22]. B02 cells (5 × 105 cells in 100 µL phosphate-buffered saline) were injected into the tail 
vein of anesthetized (130 mg/kg ketamin and 8.8 mg/kg xylazin) mice on day 0. Based on an average body 
weight of 20 g for 4-wk-old mice, risedronate (150 μg/kg body weight) was given daily to animals by subcuta-
neous injection in 100 µL PBS (vehicle). Control mice received a daily treatment with the vehicle only. On day 
32 after tumor cell inoculation, radiographs of anesthesized animals were taken with the use of MIN-R2000 film 
(Kodak) in an MX-20 cabinet X-ray system (Faxitron X-ray Corporation). Osteolytic lesions are recognized on 
radiographs as demarcated radiolucent lesions in the bone. The area of the osteolytic lesions was measured using 
a Visiolab 2000 computerized image analysis system (Explora Nova, La Rochelle, France) and the extent of 
bone destruction per animal was expressed in mm2, as described previously [22]. Anesthetized animals were 
killed by cervical dislocation following radiography at day 32. 
2.3. Bone Histology and Histomorphometry 
Bone histology and histomorphometric analysis of bone tissue sections were performed as previously described 
[22]. Vehicle- and bisphosphonate-treated tumor-bearing animals were killed at day 32, and both hind limbs 
from each animal were dissected, fixed in 80% (vol/vol) alcohol, dehydrated, and embedded in methyl-
methacrylate. A microtome (Polycut E, Reichert-Jung, Heidelberg, Germany) was used to cut 7 µm thick sec-
tions of undecalcified long bones, and the sections were stained with Goldner’s trichrome. Histologic and his-
tomorphometric analyses were performed on Goldner-stained longitudinal medial sections of tibial metaphysis 
with the use of a computerized image analysis system (Visiolab 2000). Histomorphometric measurements [bone 
volume (BV)/tissue volume (TV) and tumor volume (TV)/soft tissue volume (STV) ratios] were performed in a 
standard zone of the tibial metaphysis, situated at 0.5 mm from the growth plate, including cortical and trabecu-
lar bone. The BV/TV ratio represents the percentage of bone tissue. The TV/STV ratio represents the percentage 
of tumor tissue. 
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2.4. Sample Preparation and Characterization 
2.4.1. Sample Preparation 
Condylar tibia metaphysis were carefully sectioned under PBS (Gibco) flow by means of a sawing machine 
equipped with a diamond disk (Isomet, Buehler, Evanston, IL) into transversal sections about 2 mm thick from 
the proximal top (200 rpm speed). 
Distal surfaces of sections were first set on AFM disks (Ted Pella Inc., Redding, CA) with wax (Kerr) and 
polished under distilled water flow by means of gradually disks fixed on polishing machine (Escil, Chassieu, 
France): G 1200, G 4000 silicon carbide and 3 μm, 0.1 μm microabrasive diamond polyester disks (40 rpm 
speed). Samples were stored in PBS solution until imaging and measuring. 
The Tapping Mode™ AFM imaging at room humidity and temperature was used with Multimode AFM 
(Veeco, Santa Barbara, CA) on hydrated samples with a silicon probe MPP11100 (Veeco, Santa Barbara, CA) 
with tip radius about 10 nm and a resonant constant of 230 kHz. The roughness was determined by Root Mean 
Squared (RMS) approach on a 10 × 10 µm2 AFM images. 
2.4.2. Nanoindentation 
Nanoindentation experiments were analyzed in ambient conditions using the PicoForce microscope (Veeco, 
Santa Barbara, CA) and NW-DT-NCHR cantilevers (42 N∙m−1 of spring stiffness, 100 nm of tip radius, 
Nano World, Schaffhausen, Switzerland). Stiffness (dynamic elastic modulus, E) measurements of bone 
samples were performed as described previously [18]. Tai et al. verified that loading/unloading rates be-
tween 0.5 - 5 μm∙s−1 did not lead to statistically representative differences in calculated bone moduli [18]. 
Therefore, we carried out displacement-controlled nanoindentation by loading at a rate of 1 μm∙s−1 up to a 
trigger force of 5 μN followed by unloading at the same rate. To derive the elastic modulus, E, we use the 











where ν is the Poisson ratio and R is the tip radius. The Poisson ratio for cortical bone is 0.325 [23]. Values of 
the elastic modulus were derived from the experimental force vs. indentation curve over the indentation domain 
ranging from 20% up to 95% of the maximum indentation corresponding to the maximum applied force of 5 µN. 
A minimum of 100 nm inter-indentation spacing was considered to be sufficiently large for minimal interference 
with adjacent residual in elastically deformed zone as well as remaining stresses. 
2.5. Statistical Analysis 
The three histograms shown in Figure 4(b) have been compared using One-Way ANOVA on ranks (i.e. 
Kruskal-Wallis test; Sigmastat, Systat Software, Chicago, IL). They differ significantly (P < 0.001). Conse-
quently, a pairwise comparison was undertaken (using Dunn’s method) which showed that the three pairs of 
groups differed significantly (P < 0.05). 
2.6. Histological and Electron Microscopic Analysis 
The samples were fixed in Karnovsky fixative, postfixed with 1% osmium tetroxide in 0.1 M cacodylate buffer 
for 1 h at 4˚C, dehydrated through graded alcohol and embedded in Epon 812. Semi-thin sections were cut at 7 
µm and stained with toluidine blue, and histologically analysed by light microscopy. Ultrathin sections were cut 
at 70 nm and contrasted with uranyl acetate and lead citrate, and examined with a Morgagni 268 electron mi-
croscope. 
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